Bo Wang

Dr. Bo Wang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
WLWuwei Li
Wuwei Li
YFYuqian Fu
Yuqian Fu
BJBin Jiang
Bin Jiang
ALAaron Y. Lo
Aaron Y. Lo
GAGuillermo A. Ameer
Guillermo A. Ameer
BWBo Wang
Bo Wang

22 April 2020 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
BWBo Wang
Bo Wang
AJAlexia Johnson
Alexia Johnson
WLWuwei Li
Wuwei Li

30 January 2023 in Biofabrication
Verified
Journal Article
Closed access
BWBo Wang
Bo Wang
XWXiaolong Wang
Xiaolong Wang
AKAllen Kenneth
Allen Kenneth
ADAlexander Drena
Alexander Drena
APArsenio Pacheco
Arsenio Pacheco
JLJoy Lincoln
Joy Lincoln
While current clinical utilization of large vascular grafts for vascular transplantation is encouraging, tissue engineering of small grafts still faces numerous challenges. This study aims to investigate the feasibility of constructing a small vascular graft from decellularized amniotic membranes (DAMs). DAMs were rolled around a catheter and each of the resulting grafts was crosslinked with (a) 0.1% glutaraldehyde; (b) 1-ethyl-3-(3-dimethylaminopropyl) crbodiimidehydro-chloride (20 mM)-N-hydroxy-succinimide (10 mM); (c) 0.5% genipin; and (d) no-crosslinking, respectively. Our results demonstrated the feasibility of using a rolling technique followed by lyophilization to transform DAM into a vessel-like structure. The genipin-crosslinked DAM graft showed an improved integrated structure, prolonged stability, proper mechanical property, and superior biocompatibility. After transplantation in rat abdominal aorta, the genipin-crosslinked DAM graft remained patent up to 16 months, with both endothelial and smooth muscle cell regeneration, which suggests that the genipin-crosslinked DAM graft has great potential to be implemented as a small tissue engineered graft for future vascular transplantation.

27 December 2024 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
ASAustin Stellpflug
Austin Stellpflug
JCJustin Caron
Justin Caron
SFSamantha Fasciano
Samantha Fasciano
BWBo Wang
Bo Wang
Shue WangShue Wang
Shue Wang
Bone-derived nanoparticles enhance osteogenic differentiation of mesenchymal stem cells through upregulating Dll4 expression.

10 June 2024 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
ASAustin Stellpflug
Austin Stellpflug
JWJacob Walls
Jacob Walls
CHChristopher Hansen
Christopher Hansen
AJAmit Joshi
Amit Joshi
BWBo Wang
Bo Wang
This study developed a new type of bone-based nanoparticle (BPs) directly from the entire decellularized porcine bone, additionally encapsulating indocyanine green dye (ICG) for an in vivo monitoring capability.

22 April 2025 in Biofabrication
Verified
Journal Article
Closed access
OAO Aung
O Aung
PRPeter J Rossi
Peter J Rossi
YZYingnan Zhai
Yingnan Zhai
KAKenneth P Allen
Kenneth P Allen
MDMitchell R Dyer
Mitchell R Dyer
BWBo Wang
Bo Wang
Expanded polytetrafluoroethylene (ePTFE) grafts are Food and Drug Administration approved and effective for large vessel surgeries but face challenges in smaller vessels (Inner Diameter, ID ⩽ 6 mm) due to reduced blood flow and higher risks of thrombosis, stenosis, and infection. This study developed a vascular graft with an ID of 6 mm from decellularized human amniotic membrane (DAM graft) and compared its performance to ePTFE grafts in a porcine carotid artery model for one month. DAM grafts retained key extracellular matrix structures and mechanical properties post-decellularization, with customizable layers and stiffness to meet specific clinical needs. DAM grafts demonstrated successful carotid artery replacement, showing good surgical feasibility, patency, and post-operative recovery in all animals. In contrast to ePTFE grafts, which exhibited significant neointimal hyperplasia (NIH), poor endothelialization, and inflammation, DAM grafts displayed organized endothelial coverage, smooth muscle alignment, and reduced inflammation, minimizing NIH, thrombosis, and graft failure. These findings position DAM grafts as a promising alternative to synthetic grafts, especially for small-diameter applications. Future research should focus on improving endothelialization, exploring molecular mechanisms, and assessing long-term outcomes to further optimize DAM grafts for clinical use.